Blackstone Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Blackstone Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$38.96 - $42.75 $566,673 - $621,798	-14,545 Reduced 41.33%	20,651 $844,000
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $844,212 - $893,568	20,651 Added 141.98%	35,196 $1.49 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $294,827 - $617,289	14,545 New	14,545 $616,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Blackstone Inc, based on Form 13F filings with the SEC.

Stay updated on Blackstone Inc with notifications on news.